Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Issues related to FY2024 Appropriations
Source: Senate LDA
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lowering Costs by Improving Biosimilar Uptake Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements
Lowering Costs by Improving Biosimilar Uptake Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements Issues related to Intellectual Property Issues related to Inflation Reduction Act
Lowering Costs by Improving Biosimilar Uptake Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements Issues related to Intellectual Property Issues related to Inflation Reduction Act
Lowering Costs by Improving Biosimilar Uptake Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Lower Costs, More Cures Act of 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, H.R. 4356 and H.R. 4502 Agriculture, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, H.R. 4356 and H.R. 4502 Agriculture, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to FY 2022 Appropriations S. 2599, H.R. 4356 and H.R. 4502 Agriculture, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Further Extension of Continuing Appropriations Act, 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Further Extension of Continuing Appropriations Act, 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Prescription Drug STAR Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
More Efficient Tools to Realize Information for Consumers Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
More Efficient Tools to Realize Information for Consumers Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Medicare Prescription Drug Price Negotiation Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Prescription Drug Price Negotiation Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Elijah E. Cummings Lower Drug Costs Now Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
ACCESS for Biosimilars Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
ACCESS for Biosimilars Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
ACCESS for Biosimilars Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
ACCESS for Biosimilars Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
ACCESS for Biosimilars Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
ACCESS for Biosimilars Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Families First Coronavirus Response Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Families First Coronavirus Response Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
CARES Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
CARES Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
CREATES Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
CREATES Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Ensuring Timely Access to Generics Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Ensuring Timely Access to Generics Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Affordable Prescriptions for Patients Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Affordable Prescriptions for Patients Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Lower Health Care Costs Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Lower Health Care Costs Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Strengthening America’s Supply Chain and National Security Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Strengthening America’s Supply Chain and National Security Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Increasing Access to Biosimilars Act of 2020
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Biologic Patent Transparency Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Biologic Patent Transparency Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Medicare Drug Price Negotiation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
For the People Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
For the People Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
For the People Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
For the People Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
For the People Act of 2019
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part B Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Further Extension of Continuing Appropriations Act, 2021
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act The Access to Prescription Digital Therapeutic Act of 2023 (S. 723/H.R. 1458)
Prescription drug manufacturing and supply chains
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act
Prescription drug manufacturing and supply chains
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act
Issues related to FY2024 Appropriations
Filing targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Prescription drug manufacturing and supply chains
Issues related to Medicare Part D redesign Rebate reform Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars Issues regarding implementation of the Inflation Reduction Act Issues related to the Treat and Reduce Obesity Act
Issues related to FY2024 Appropriations
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax Issues related to Intellectual Property Issues related to Inflation Reduction Act
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements Issues related to Intellectual Property Issues related to Inflation Reduction Act
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Prescription drug manufacturing and supply chains
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements Issues related to Intellectual Property Issues related to Inflation Reduction Act
Prescription drug manufacturing and supply chains
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Prescription drug manufacturing and supply chains
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Prescription drug manufacturing and supply chains
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to FY 2022 Appropriations S. 2599, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars Issues related to the 340B program Issues related to tax
Issues related to FY 2022 Appropriations S. 2599, H.R. 4356 and H.R. 4502 Agriculture, Rural Development, Food and Drug Administration Related Agencies Appropriations Act 2022
Issues related to Biosimilars Issues related to BBBA and Biosimilars
Issues related to Biosimilars
Prescription drug manufacturing and supply chains
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars Issues related to the 340B program Issues related to tax
Issues related to Biosimilars
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars Issues related to the 340B program Issues related to tax
Prescription drug manufacturing and supply chains
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars
Issues related to FY 2022 Appropriations
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Issues related to Medicare Part D redesign, rebate reform, and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost-sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Biosimilars S. 3466/H.R. 4597, and H.R. 6179/S. 4134
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill) Issues Related to Fiscal Year 2021 Appropriations for the Labor, Health and Human Services, and Education Agencies
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part B Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and value Issues related to ICD-10 diagnosis codes Prescription drug manufacturing and supply chains Issues regarding the ongoing COVID-19 public health emergency Issues related to Biosimilars (including H.R. 7047) Issues related to the 340B program Issues related to tax Issues related to reauthorizing the Prescription Drug and Biosimilar User Fee Agreements
Issues related to Biosimilars Issues related to BBBA and Biosimilars
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Prescription drug manufacturing and supply chains
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FY 2022 Appropriations
Issues related to Medicare Part D redesign, rebate reform and international pricing index (including H.R. 3, H.R. 19) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Prescription drug manufacturing and supply chains
Issues related to FY 2022 Appropriations
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D redesign, rebate reform and international pricing index (no specific bills) 2021 Notice of Benefit and Payment Parameters and cost sharing assistance Medicaid Drug Rebate Program (MDRP), including value-based purchasing (VBP) arrangements and line extensions Issues related to Biosimilars H.R. 13919 (Issues related to COVID-19 relief and the Medicaid rebate cap)
Issues related to Biosimilars
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Biosimilars S. 3466, H.R. 4597, and H.R. 6179, S. 4134
Prescription drug manufacturing and supply chains
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Diabetes and Heart Health Awareness S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Cut of 2019 H.R. 748 CARES Act H.R. 6201 Families First Coronavirus Response Act H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 S. 3538, the Strengthening Americas Supply Chain and National Security Act (Sen. Rubios bill)
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
Drug and Biologic Patent Policy Biopharmaceutical Innovation and Patent Policy Issues S.659 Biologic Patent Transparency Act Bayh-Dole March-in Rights Issues S. 1416, Affordable Prescriptions for Patients Act
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Biosimilars Pass-Through Status in Part B Manufacturer Liability in the Medicare Part D Donut Hole H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 107 - To amend Title XIX of the Social Security Act to Sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs CMS proposed removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals CMS Advanced Notice of Proposed Rulemaking on International Pricing Index (IPI) Model H.R. 2113- Prescription Drug Sunshine, Transparency, Accountability, and reporting (STAR) Act Biosimilars Part B reimbursement issues H.R. 448 and S.99 - Medicare Drug Price Negotiation Act of 2019 Issues related to the Medicaid Drug Rebate Program Issues related to reform of the Medicare Part D Program
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
Legislative proposals to amend FARA H.R. 1 - For the People Act of 2019
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordable and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act Related to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act of 2019 The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements S. 1895, the Lower Health Care Costs Act of 2019 H.R. 2113, Prescription Drug STAR Act H.R. 2296, the Fair Drug Pricing Act of 2019
Trade Agreement USMCA and related policy issues Intellectual Property and Market Access Policy Issues
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
Diabetes and Heart Health Awareness COPD Awareness H.R. 447-Affordavble and Safe Prescription Drug Importation Act S.97 - Affordable and Safe Prescription Drug Importation Act S.1169 - Bill to amend the Federal Food, drug and Cosmetic Act elated to Citizens Petitions S.61 and H.R. 478 - Safe and Affordable Drugs from Canada Act of 2019 Issues related to Prescription Drug Counterfeiting and Importation Issues related to Transparency Compulsory Licensing Policy Issues Binding Arbitration Policy Issues Biosimilar development, approval, and reimbursement policy issues H.R. 1520, Purple Book Continuity Act of 2019 Biosimilar Education Issues H.R. 965 - CREATES Act The Patient Affordability, Value, and Efficient Act (Draft Legislation) and issues related to value based purchasing arrangements
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, U.S. Trade & Development Agency (USTDA)